search
Back to results

Pain Treatment After TKA With LIA and Intra-articular Continuous Infusion Pump

Primary Purpose

Postoperative Pain Management

Status
Completed
Phase
Phase 4
Locations
Sweden
Study Type
Interventional
Intervention
Ropivacaine
Placebo
Sponsored by
Region Skane
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Postoperative Pain Management focused on measuring Total Knee Arthroplasty

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Primary osteoarthritis of the knee necessitating total knee replacement
  • Patients who understand the conditions of the study and are willing to participate for the length of the prescribed follow-up

Exclusion Criteria:

  • Known allergy to local anaesthetics or other contraindication for the use of local anaesthetics.
  • Treatment with Warfarin.
  • Bilateral operation

Sites / Locations

  • Department of Orthopedics, Skane University Hospital, Lund University

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Ropivacaine in the pump

Placebo in the pump

Arm Description

The intra-articular Continuous Infusion Pump is filled with Ropivacaine,10 mg/ml, set at 2 ml/hour for 48 hours postoperatively.

The intra-articular Continuous Infusion Pump is filled with NaCl, set at 2 ml/hour for 48 hours postoperatively.

Outcomes

Primary Outcome Measures

Change in postoperative pain
The patient are asked to grade their pain on a VAS-scale (0-100)twice daily for the first 4 days after the TKA operation and at the 2 weeks follow-up. Changes in pain during this time frame are recorded to see if there are any differences between the two groups.

Secondary Outcome Measures

Extra oral analgesia consumption
All extra analgesia consumption are noted during the first 4 postoperative days. All patients have a standard pain management medication (depending on weight, age and sex) and only extra doses are noted.

Full Information

First Posted
October 30, 2012
Last Updated
November 24, 2014
Sponsor
Region Skane
search

1. Study Identification

Unique Protocol Identification Number
NCT01726686
Brief Title
Pain Treatment After TKA With LIA and Intra-articular Continuous Infusion Pump
Official Title
Evaluation of Intra-articular Continuous Infusion Pump With Ropivacaine in Addition to Local Infiltration Analgesia (LIA) in Total Knee Arthroplasty (TKA). A Placebo Controlled Randomised Trial.
Study Type
Interventional

2. Study Status

Record Verification Date
November 2014
Overall Recruitment Status
Completed
Study Start Date
February 2010 (undefined)
Primary Completion Date
July 2011 (Actual)
Study Completion Date
April 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Region Skane

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the effect on postoperative pain and function by adding intraarticular continuous infusion pump with local anesthetic after total knee arthroplasty where local infiltration analgesia has already been given.
Detailed Description
200 patients with osteoarthritis (OA) of the knee necessitating total knee arthroplasty are entered into the study. All patients are given a standard protocol of analgesics pre- and postoperatively. All patients get periarticular LIA-injection (150 ml) with a total of 300 mg Ropivacaine, 30 mg Toradol and 0.5 mg Adrenalin. In the end of the operation all patients get an epidural type of catheter intraarticular with a coupled continuous infusion pump that delivers 2 ml per hour and are disconnected after 48 hours. The University hospital pharmacy has prepared 200 pumps; 100 Active substance pumps with 100 ml Ropivacaine (10mg/ml) and 100 placebo pumps with 100 ml sodium chloride (NaCl). All patients are by computer software randomized to receive either active or placebo pump. Only one nurse, not involved in neither the operation nor the after treatment, has the key to what substance it is in the numbered pumps. Thus, it is a double blinded trial during the whole follow up period. Before the operation the patients are asked to fill out a knee specific outcome questionnaire, the Knee injury and Osteoarthritis Outcome Score (KOOS), and a general outcome questionnaire, the Euroqol (EQ-5D), and the knee range of motion is measured by a physiotherapist. After the operation the patients are monitored at the ward by the nurses and physiotherapists. The level of pain is measured twice daily (noon and 8 PM) according to the Visual-Analog-Scale (VAS). The range of motion and is measured on day 4 and at the day 14 and day 30 follow up. The number of days the patients need to stay in hospital after operation are registered. The amount of extra doses of analgesics the patient requires are registered as well as the complications (illness, wound problems, infections etc). The patients are to be followed clinically for 2 years as well as with outcome questionnaires.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postoperative Pain Management
Keywords
Total Knee Arthroplasty

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
200 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Ropivacaine in the pump
Arm Type
Active Comparator
Arm Description
The intra-articular Continuous Infusion Pump is filled with Ropivacaine,10 mg/ml, set at 2 ml/hour for 48 hours postoperatively.
Arm Title
Placebo in the pump
Arm Type
Placebo Comparator
Arm Description
The intra-articular Continuous Infusion Pump is filled with NaCl, set at 2 ml/hour for 48 hours postoperatively.
Intervention Type
Drug
Intervention Name(s)
Ropivacaine
Other Intervention Name(s)
Naropin, Narop
Intervention Description
100 ml Ropivacaine 10mg/ml in a continuous infusion pump set at 2 ml/hour
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Change in postoperative pain
Description
The patient are asked to grade their pain on a VAS-scale (0-100)twice daily for the first 4 days after the TKA operation and at the 2 weeks follow-up. Changes in pain during this time frame are recorded to see if there are any differences between the two groups.
Time Frame
The first 4 postoperative days at noon and 8 PM
Secondary Outcome Measure Information:
Title
Extra oral analgesia consumption
Description
All extra analgesia consumption are noted during the first 4 postoperative days. All patients have a standard pain management medication (depending on weight, age and sex) and only extra doses are noted.
Time Frame
First 4 postoperative days
Other Pre-specified Outcome Measures:
Title
Number of postoperative days in hospital
Description
The number of days the patient needs to stay in hospital after operation are noted
Time Frame
Duration of hospital stay, an expected time frame of 4-5 days
Title
Pre- and postoperative knee range of motion
Description
The range of motion in the affected knee are registered with a goniometer at the preoperative admission for operation, about 2 weeks prior to the operation and then on day 4, 14 and 30 postoperatively.
Time Frame
At preoperative admission for operation (about 2 weeks prior), day 4, 14 and 30 postoperatively
Title
Postoperative complications
Description
All complications postoperatively are registered for the first 2 years.
Time Frame
2 years postoperatively
Title
Knee specific and general questionaire
Description
The patients are asked to fill out the general health questionaire EQ-5D as well as the knee specific questionaire KOOS preoperatively at the admission for surgery (about 2 weeks before the operation) and at 1 and 2 year follow up.
Time Frame
preoperatively (about 2 weeks prior to op), 1 and 2 years postoperatively

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Primary osteoarthritis of the knee necessitating total knee replacement Patients who understand the conditions of the study and are willing to participate for the length of the prescribed follow-up Exclusion Criteria: Known allergy to local anaesthetics or other contraindication for the use of local anaesthetics. Treatment with Warfarin. Bilateral operation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gunnar Flivik, MD PhD
Organizational Affiliation
Dept of Orthopedics, Skane University Hospital, Lund University, Sweden
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Orthopedics, Skane University Hospital, Lund University
City
Lund
Country
Sweden

12. IPD Sharing Statement

Learn more about this trial

Pain Treatment After TKA With LIA and Intra-articular Continuous Infusion Pump

We'll reach out to this number within 24 hrs